Solving the Prisoner’s Dilemma: Product Innovation, Solutions-Focused Business Models Can Help Counter Declining Medtech ROC

article image

Return on Capital performance for healthcare product manufacturers has been steadily declining. While medtech companies typically attempt to counter ROC declines with cost-savings initiatives, they may achieve more substantial, long-term value by boosting innovation and shifting toward a business model focused on transformational products and solutions that create step-change customer value. By Yakir Siegal, Glenn Snyder, Myriam Lopez, and Lauren Morton, Deloitte Consulting

Deloitte research shows that Return on Capital performance (a ratio used to measure profitability and to determine a company’s potential to create value) has been steadily declining for healthcare product manufacturers.


This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Sign up for All-Access

Join our global community with a subscription to both MedTech Strategist and Market Pathways for one low price.



We're here to help! Please contact us at: